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PURPOSE: To improve the selection of advanced colorectal cancer patients to panitumumab by optimizing the
assessment of RAS (KRAS-NRAS) mutations. EXPERIMENTAL DESIGN: Using a centralized pyrosequencing RAS
assay, we analyzed the tumors of 94 patients, wild-type for KRAS mutations (codons 12 to 13) by Sanger
sequencing (SS), treated with panitumumab. RESULTS: By SS analysis, 94 (62%) of 152 patients were wild-type
and their objective response rate to panitumumab was 17%. We first optimized the KRAS test, by performing an
accurate tissue-dissection step followed by pyrosequencing, a more sensitive method, and found further
mutations in 12 (12.8%) cases. Secondly, tumors were subjected to RAS extension analysis (KRAS, exons 3 to 4;
NRAS exons 2 to 4) by pyrosequencing that allowed to identify several rare mutations: KRAS codon 61, 5.3%;
codon 146, 5.3%; NRAS, 9.5%. Overall, RAS mutation rate was 32.9%. All patients with additional RAS mutations
had progressive or stable disease, except 3 patients with mutations at codon 61 of KRAS or NRAS who
experienced partial (2 cases) or complete response. By excluding from the analysis 11 cases with mutations at
codons 61, no patient was responsive to treatment (P = .021). RAS wild-type versus RAS mutated cases had a
significantly better time to progression (P = .044), that resulted improved (p = .004) by excluding codon 61
mutations. CONCLUSION: This study shows that by optimizing the RAS test it is possible to significantly improve
the identification of patients who do not gain benefit of panitumumab. Prospective studies are warranted to
determine the clinical significance of rare mutations.
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The major challenge related to the optimal administration of target
therapy in oncology is the identification of the subgroups of patients who
are more likely to be responsive or resistant to a selective agent [1]. The
proper selection of patients to be treated by any targeted drug should be
based on the availability of a specific predictive tool to be detected in each
single patient allowing a favorable cost/efficacy ratio [2].
The therapeutic paradigm in metastatic colorectal cancer (mCRC)
changed after the discovery that mutated tumor KRAS status is
associated with lack of response to therapy with epidermal growth
factor receptor (EGFR) monoclonal antibodies (mAbs). [3–8].
Specifically, patients with KRAS mutations in exon 2 are resistant
to anti-EGFR. KRAS is a small transducer G protein and acquired
KRAS codon 12 or 13 gain-of-function mutations leads to constitutive
signaling through the EGF pathway and to downstream activation of
MAPK and PI3K dependent pathways [9,10]. However, KRAS
determination alone does not have an absolute predictive capability.
In fact, even among wild-type tumors the percentage of responsiveness
to anti-EGFR agents is approximately 15% to 25% [3–8,11].
Recent results by Douillard et al. [12] demonstrated that additional
RAS mutations predicted resistance in patients treated with first-line
panitumumab and FOLFOX4. They [12] found that 17% of patients
with non-mutated KRAS exon 2 had other mutually exclusive
mutations associated with lack of response to therapy. Similarly,
Peeters et al. [13] evaluated, in a retrospective analysis, response to
panitumumab monotherapy by using a parallel multigene sequencing
technique to determine KRAS, additional RAS activating mutations
(KRAS codon 61; NRAS codons 12-13-61) and BRAF. The authors
[13] found improved response rate among the patients with wild-type
KRAS, NRAS, and BRAF tumors.
We evaluated a cohort of 152 patients of whom 94 with tumors
treated with panitumumab, on the base of on-site assessment of
KRAS wild-type, after failure of at least 2 previous schedules of
treatment to determine: 1) the impact of a centralized analysis of
KRAS status by a more accurate tissue dissection and the more
sensitive pyrosequencing method, and 2) by extending the study to
additional RAS-activating mutations, with the aim to identify more
potentially non-responsive patients initially classified KRAS wild-type.




Eligible patients for the RASMES multicentre study had pathologic
diagnosis of colorectal carcinoma and radiological documentation of
metastatic disease (Stage IV; Dukes D). All the patients had received
administration of fluoropyrimidine, oxaliplatin and irinotecan, and had
disease progression. Other key eligible criteria included: determination of
KRAS status by Sanger sequencing, 18 years or older, Eastern
Cooperative Oncology Group performance status score of 0 to 2, at
least two prior chemotherapeutic inclusive adjuvant therapy regimens,
measurable disease, adequate bone marrow, hepatic, and renal functions.
Exclusion criteria included symptomatic brain metastases, interstitial
pneumonitis or pulmonary fibrosis, prior anti-EGFR agent treatment,
and KRAS mutated tumors.
Panitumumab was administered by a 60-minute intravenous
infusion at the dose of 6 mg/kg once every 2 weeks until patients
progressed or unacceptable toxicity developed.All patients with measurable disease at the baseline central review
had their objective tumor response assessed by the investigator and
blinded central radiology review using modified Response Evaluation
Criteria in Solid Tumors (RECIST) [14] every 8 weeks, and,
thereafter until disease progression, and confirmed no less than
4 weeks after the criteria for response were first met. At the discretion
of the investigator, patients could be evaluated for radiographic tumor
assessment after developing symptoms consistent with disease
progression. All patients were followed for survival approximately
every 3 months up to 2 years.
Time to progression was calculated as the time (in weeks or
months) from the basal evaluation of disease before starting
panitumumab treatment to the time to the first radiological or
clinical progression of disease. Local and central reviews were
conducted for all assessments.
The study protocol was approval by The San Filippo Neri Hospital
institutional review board and by independent Ethical Committees at
each participating Center. Informed consent was obtained from each
subject included in the study.
Biomarker Analysis
From a cohort of 152 patients with advanced colon-rectal cancer
assessed on-site for KRAS codon 12 to 13 mutation status by
laboratories who had undergone external quality program, 94 patients
with wild-type KRAS were treated with panitumumab after failure of
at least 2 previous schedules of treatment. These 94 cases were re-
analyzed in a centralized laboratory (University of Chieti) for RAS
(KRAS/NRAS) mutations status. Tissue blocks from all these 94
patients obtained from primary surgical resection and before all lines
of therapy were sent to the referral laboratory where 3 serial 4-μm-
thick histological sections were obtained for morphological and
molecular analysis. One section was stained with hematoxylin-eosin
and reviewed by 2 pathologists (A.M.and F.B.) to select the optimal
tumor areas to be analyzed. The other two sections were carefully
micro-dissected under a dissecting microscope to exclude surrounding
normal tissues, stromal and inflammatory areas, and to assure the
presence of at least 70% of neoplastic cells in the selected areas which
were scraped off the glass slide by a sterile needle and then xylene de-
paraffinized before digestion with proteinase K at 56 °C overnight.
DNA extraction was performed using the spin column procedure
(QIAamp DNA Mini Kit; Qiagen, Valencia, CA) on the QiaCube
platform (Qiagen, Valencia, CA) and the recovered DNA quantified
by NanoDrop 2000 (Thermo Scientific).
DNA samples from the 94 KRAS wild type patients were analyzed for
codon 12 to 13 of KRAS [15] and for additional mutations in KRAS
(exon 3 at codon 61, exon 4 at codons 117 and 146) andNRAS (exon 2
at codons 12 to 13, exon 3 at codon 61, and exon 4 at codons 117 and
146). RAS mutational analysis was performed by pyrosequencing using
the KRAS Pyro Kit, NRAS Pyro Kit, RAS Extension Pyro Kit (Qiagen,
Valencia, CA) according to the manufacturer's recommendations.
Sequencing was performed on the PyroMark Q24 platform (Qiagen)
that utilizes a pyrosequencing data analysis software (PyroMark Q24
software (Qiagen)) developed to increase the efficiency and consistency
of pyrosequencing data analysis.
Statistical Analysis
The variables measured in the study were investigated for
association by using the Fisher's exact test or χ2 test as appropriate.
Progression-free survival was measured for each patient from the day
Table 2. Frequency of All RAS Mutations.
MUTATION Number of patients (%)
KRAS codons 12-13 12 (13%)
KRAS codon 61 5 (5%)
KRAS codon 146 5 (5%)
NRAS codon 61 6 (6%)
NRAS codons 12-13 3 (3%)
TOTAL 31 (32.9%)
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were estimated using the Kaplan–Meier method, and differences
among them evaluated by the log-rank Mantel Cox test. A P b .05
was considered as significant. All statistical analyses were performed
using the SPSS pack version 15.
Results
Patients
KRAS status was ascertained in mCRC tumors from 152 patients
evaluated for the study of whom 94 (62%) were wild-type and 58
(38%) had KRAS codon 12 or 13 mutations.
The clinic-pathologic characteristics of the cohort of 94 patients
with KRAS wild-type tumors, as determined by a direct sequencing
method on site in each single participating center, are reported on
Table 1. Severe drug-related side effects were rare particularly
regarding gastrointestinal, hematological, and metabolic toxicities. As
expected, the majority of grade 3 to 4 toxicities were related to
dermatological side effects (12%).
As a first step analysis we re-evaluated in a central referral
laboratory (A.M. and F.B.) all the tumor samples of the 94 KRAS
wild-type patients by an accurate tissue dissection and by a more
sensitive pyrosequencing method of exon 12 and 13. This analysis
was capable to detect 12 more (12.8%) KRAS mutated tumor cases.
Secondly, we evaluated other RAS mutations by a comprehensive
pyrosequencing method and we found a further 19 (20.2%)
mutations (5 in KRAS codon 61, 5 in KRAS codon 146; 6 in
NRAS codon 61 and 3 in NRAS codon 12 to 13) (Table 2). Overall,
by applying both the above analyses we were able to identify, besides
the standard direct sequencing KRAS method performed on-site in
each Center and used to enroll the patients for therapy, a total of 31
RAS mutated tumors (32.9%).Table 1. Patient Clinico-Pathologic Characteristics.












Liver (only) 20 (21%)
Lung (only) 14 (15%)
Lymph nodes (only) 2 (2%)
Skeletal (only) 2 (2%)
Peritoneum (only) 4 (5%)
Multiple sites 52 (55%)
Number of target lesions









* All treated with oxaliplatin-based adjuvant therapy.Efficacy According to Tumor RAS Status
The ORR to panitumumab was 17% with 3 patients achieving a
complete response (CR) and 13 patients with a partial response (PR).
Another 28 cases (29.7%) had a stable disease (SD) lasting at least
3 months. The clinical benefit was 46.7%.
The overall cohort of patients assessed in each Center for KRAS
analysis, for the central laboratory review and extended RAS
evaluation is shown in Figure 1.
In the series of the 12 patients with KRAS codon 12 to 13
mutations, as detected by the central pyrosequencing method, 10
cases had PROGRESSION DISEASE (PD), and 2 cases had SD.
In the cohort of the 19 tumors in which the extended RAS analysis
showed further mutations, 11 patients experienced PD, 1 patient
achieved a CR, other 2 a PR and 5 had a SD. In detail, of the 5 cases
with KRAS codon 146 mutation, 3 had PD and 2 had stable disease.
Of the 5 cases with KRAS codon 61 mutations, 4 had a PD and one a
PR. Among the 9 patients with NRAS mutated tumors, 7 showed a
mutation at codon 61 and 2 at codon 12 to 13. Of the 7 cases with
NRAS codon 61 mutations, 3 had a PD; 2 SD, one a PR, and one a
CR; of the 2 cases mutated at codon 12 to 13 of NRAS, 1 had a PD
and 1 a SD. In summary, responses (1 CR and 2 PR) were observed
only in patients having tumors with KRAS and NRAS mutations at
codon 61. In Table 3 are reported the ORR of the 11 patients with
tumors harboring KRAS and NRAS codon 61 mutations.
By Fisher's exact 2-sided test we correlated ORR with the RAS
gene status. In all the 31 cases with RAS mutations we found no
statistically significant difference on response versus non response
between RAS mutated and wild-type tumors (P = .25).By excluding
from the analysis the 11 cases harboring RAS codon 61 the difference
in ORR between patients with wild-type tumors versus RAS mutated
ones reached statistical significance (P = .02).
Regarding TTP, the patients with wild-type tumors had a
statistically significant better TTP as compared to those with RAS
mutated disease with 7.4 ± .85 weeks versus 5.2 ± .91 weeks (log
rank–Mantel Cox, P = .044) (Figure 2A). Similar to the results
observed on ORR also regarding TTP the deletion from the analysis
of the cases harbouring RAS codon 61 mutations enhanced the
significance in outcome between wild-type versus mutated tumors
with 7.4 ± .85 weeks versus 3.94 ± .43 weeks (P = .04) (Figure 2B).
Discussion
Panitumumab was approved for third-line therapy in mCRC after
publication of the results of phase III trial by Van Cutsem et al. [16]
demonstrating that this anti-EGFR agent significantly improved
progression-free survival, with a good toxicity profile, as compared to
best supportive care.
The subsequent retrospective analysis by Amado et al. [3] showed
that the patients with mutant KRAS codon 12 and 13 tumors are
unlikely to benefit from panitumumab therapy. Consequently,
clinical guidelines up to 2012 suggested that only mCRC patients
Figure 1. Overall cohort of patients assessed in the study.
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agent. Recently another two phase III trials added relevant
information on the relationship between RAS gene and efficacy to
panitumumab. The first study by Peeters et al. [11] confirmed the
better efficacy of the FOLFIRI-panitumumab versus FOLFIRI alone
as second-line treatment in patients with mCRC and wild-type KRAS
tumors. The second study by Douillard et al. [12] allowed a further
significant step in the identification of the subpopulation of patients
potentially resistant to the regimen FOLFOX4-panitumumab by
extending the analysis to all known RAS mutations. The authors [12]
showed that RAS mutations, in addition to KRAS exon 2 mutations,
improved the benefit-risk profile of panitumumab-FOLFOX4 as
first-line treatment. The study [12] identified 17% more patients to
be excluded to therapy and allowed for a more selective selection of
patients for such a therapeutic regimen.Table 3. Correlation Between RAS Codon 61 Mutations and ORR.
Case TYPE of mutation ORR
01 KRAS Q61H PD
02 KRAS Q61L PD
03 KRAS Q61H PD
04 KRAS Q61H PD
05 KRAS Q61H PR
06 NRAS Q61R CR
07 NRAS Q61H PD
08 NRAS Q61H PD
09 NRAS Q61R PR
10 NRAS Q61R SD
11 NRAS Q61L PDIn the present study the patients were prospectively treated with
panitumumab monotherapy on the basis of determination of KRAS
performed on-site in each single Center. The additional molecular
analyses performed in the centralized laboratory allowed to improve
the results of identification of KRAS mutations by using a more
sensitive pyrosequencing method and by assessing other RAS
mutations. Among the 94 patients with KRAS wild-type tumors as
for the standard on-site direct sequencing technique we identified a
further 31 RAS mutations (32.9%).
Recent reports have suggested that rare KRAS mutations may have
different significance with respect to responsiveness to anti-EGFR mAbs.
In particular, controversial data are reported on KRAS codon
G13D with a number of small retrospective studies that have
reported improved outcomes in some patients with such mutations
[17–19,11,20–23]. In our series of cases all the 4 patients with
G13D mutations had PD in accordance to the results recently
reported by Schirripa et al. [24].
Interestingly, in the cohort of tumors analyzed we revealed a
relatively high frequency of rare RAS mutations possibly due to the
high sensitive methodology applied. This allowed us to correlate a
relatively high number of tumors harboring rare mutations with
clinical outcome.
There is some evidence suggesting that mutations at KRAS and
NRAS codons 61 and 146 have similar impact of mutations at
codons 12 and 13. We found that among the 5 tumors harboring
codon 146 mutations we observed 2 SD and 3 PD. More
controversial was the correlation between codon 61 mutations and
outcome. Among the 11 cases we observed 3 responsive patients (1 CR;
Figure 2. (A) Time to progression by RAS status: RAS wild
type tumors ( ), RASmutated tumors ( ). (B) Time to
progression by RAS status: RASwilde type tumors ( ), RAS
mutated tumors by excluding codon 61 mutations from the
analysis ( ).
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patient with codon Q61H out of the 6 patients carrying KRAS codon
61 mutations had a PR.
These results, as the clinical significance of 61 codon mutations is
concerned, if confirmed in a larger prospective series, may suggest that
their determination may be not useful for clinical making decisions on
the administration of panitumumab treatment.
The analysis of correlation between RAS wild-type versus the 31
cases mutated and response rate found no statistically significant
difference in outcome. However, when the 11 tumors harboring the
61 codon mutations were excluded from the analysis the difference in
ORR reached a statistically significant level. Similarly, regarding TTP
the deletion of 61 codon mutants allowed to enhance the significance
in outcome between wild-type versus mutated tumors. It should be
taken into account that our analysis was retrospective and exploratory
in nature and performed in a small number of patients, therefore data
needs to be interpreted with caution.
The correlation between RAS mutations with low frequencies such
as codon 61 and 146 and clinical outcome of patients treated with anti-EGFR mAbs, needs prospective [23] large predictive pooled trials or
meta-analyses of more studies in order to better define their clinical
significance and possible predictive value to future innovative therapeutic
strategies for MCRC resistant to anti-EGFR therapy [25,26].
Conclusions
The results of our study agree with Douillard's data [10] on the
relevance of determination of KRAS as a negative predictive tool for
panitumumab-based treatment. The high sensitive methods applied
allowed us to identify more RAS mutations than the standard
methods useful to spare unnecessary treatments to primary resistant
tumors in the future.
On the basis of the most available data and consistently with current
treatment guidelines for administration of panitumumab in mCRC,
only the patients with extended RAS wild-type tumors are likely to be
responsive and are eligible for anti-EGFR targeted therapy.
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